Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the ...

Eli Lilly is paying up to $630m for a Phase I MASH candidate from OliX Pharmaceuticals, diversifying its pipeline with an RNA ...

Eli Lilly strengthens its pipeline with AdvanCell for targeted alpha therapies and partners with OliX to advance OLX75016 for MASH and cardiometabolic diseases.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

We recently published a list of 10 Important News Updates Investors Shouldn’t Miss. In this article, we are going to take a ...

We recently compiled a list of the 13 Best Dividend Growth Stocks With 10%+ Yearly Increases. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against ...

The stock's fall snapped a four-day winning streak.

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

OliX Pharmaceuticals announced a global licensing agreement with Eli Lilly (LLY). This collaboration focuses on the development and ...

Eli Lilly (NYSE:LLY) has filed for a six-part note offering, with the aggregate principal amount of the notes offered ...

The results were consistent with the preliminary results Eli Lilly shared in January, which disappointed investors.

Eli Lilly expects to provide results from a study in people with obesity and osteoarthritis of the knee in 2025.